Moreover, studies have revealed that eIF3e functions as a novel regulator of hypoxia-inducible 2α (HIF2α) activity, suggesting that targeted silencing of eIF3e may hold therapeutic potential for treating hypoxia-related ischemic disorders, such as cardiac and cerebral ischemia, cutaneous injuries, and various vascular obstructive diseases [17–19]. Here, EIF3E is linked to Cerebral ischemia.